Monoclonal Antibodies May No Longer Be a Match for Emerging COVID Strains
Tixagevimab/cilgavimab (Evusheld) and bebtelovimab are likely ineffective against approximately 60% of currently circulating Omicron variants, creating a big gap in protection, particularly for immunocompromised individuals, researchers from a Harvard Medical School-led consortium said at a briefing on Thursday. This is a “big loss,” said Jacob Lemieux, MD, PhD, of the Massachusetts Consortium on Pathogen Readiness […]